TY  - JOUR
AU  - Dopsaj, Milivoj
AU  - Tan, Wilhelmina
AU  - Perović, Vladimir
AU  - Stajić, Zoran
AU  - Milosavljević, Nemanja
AU  - Paessler, Slobodan
AU  - Makishima, Tomoko
PY  - 2024
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12994
AB  - Virtual reality (VR) is a computer-created 3D environment with a focus on realistic scenes and pictures created for entertainment, medical and/or educational and training purposes. One of the major side effects of VR immersion reported in the scientific literature, media and social media is Visually Induced Motion Sickness (VIMS), with clinical symptoms such as disorientation, nausea, and oculomotor discomfort. VIMS is mostly caused by the discrepancy between the visual and vestibular systems and can lead to dizziness, nausea, and disorientation. In this study, we present one potential novel solution to combat motion sickness in VR, showcasing a significant reduction of nausea in VR users employing the META Quest 2 headsets in conjunction with a whole-body controller. Using a neurodigital approach, we facilitate a more immersive and comfortable VR experience. Our findings indicate a marked reduction in VR-induced nausea, paving the way to promote VR technology for broader applications across various fields.
T2  - Neuroscience Letters
T1  - Novel neurodigital interface reduces motion sickness in virtual reality
VL  - 825
SP  - 137692
DO  - 10.1016/j.neulet.2024.137692
ER  - 

@article{
author = "Dopsaj, Milivoj and Tan, Wilhelmina and Perović, Vladimir and Stajić, Zoran and Milosavljević, Nemanja and Paessler, Slobodan and Makishima, Tomoko",
year = "2024",
abstract = "Virtual reality (VR) is a computer-created 3D environment with a focus on realistic scenes and pictures created for entertainment, medical and/or educational and training purposes. One of the major side effects of VR immersion reported in the scientific literature, media and social media is Visually Induced Motion Sickness (VIMS), with clinical symptoms such as disorientation, nausea, and oculomotor discomfort. VIMS is mostly caused by the discrepancy between the visual and vestibular systems and can lead to dizziness, nausea, and disorientation. In this study, we present one potential novel solution to combat motion sickness in VR, showcasing a significant reduction of nausea in VR users employing the META Quest 2 headsets in conjunction with a whole-body controller. Using a neurodigital approach, we facilitate a more immersive and comfortable VR experience. Our findings indicate a marked reduction in VR-induced nausea, paving the way to promote VR technology for broader applications across various fields.",
journal = "Neuroscience Letters",
title = "Novel neurodigital interface reduces motion sickness in virtual reality",
volume = "825",
pages = "137692",
doi = "10.1016/j.neulet.2024.137692"
}

Dopsaj, M., Tan, W., Perović, V., Stajić, Z., Milosavljević, N., Paessler, S.,& Makishima, T.. (2024). Novel neurodigital interface reduces motion sickness in virtual reality. in Neuroscience Letters, 825, 137692.
https://doi.org/10.1016/j.neulet.2024.137692

Dopsaj M, Tan W, Perović V, Stajić Z, Milosavljević N, Paessler S, Makishima T. Novel neurodigital interface reduces motion sickness in virtual reality. in Neuroscience Letters. 2024;825:137692.
doi:10.1016/j.neulet.2024.137692 .

Dopsaj, Milivoj, Tan, Wilhelmina, Perović, Vladimir, Stajić, Zoran, Milosavljević, Nemanja, Paessler, Slobodan, Makishima, Tomoko, "Novel neurodigital interface reduces motion sickness in virtual reality" in Neuroscience Letters, 825 (2024):137692,
https://doi.org/10.1016/j.neulet.2024.137692 . .

TY  - JOUR
AU  - Đukić, Ivana
AU  - Kaličanin, Nevena
AU  - Senćanski, Milan V.
AU  - Pajović, Snežana B.
AU  - Milićević, Jelena S.
AU  - Prljić, Jelena
AU  - Paessler, Slobodan
AU  - Prodanović, Radivoje
AU  - Glišić, Sanja
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10629
AB  - Drug resistance is a critical problem in health care that affects therapy outcomes and requires new approaches to drugdesign. SARS-CoV-2 Mpro mutations are of concern as they can potentially reduce therapeutic efficacy. Viral infections are amongst themany disorders for which nutraceuticals have been employed as an adjunct therapy. The aim of this study was to examine the potentialin vitro activity of L-arginine and vitamin C against SARS-CoV-2 Mpro. Methods: The Mpro inhibition assay was developed by cloning,expression, purification, and characterization of Mpro. Selected compounds were then screened for protease inhibition. Results: Largininewas found to be active against SARS-CoV-2 Mpro, while a vitamin C/L-arginine combination had a synergistic antiviral actionagainst Mpro. These findings confirm the results of our previous in silico repurposing study that showed L-arginine and vitamin C werepotential Mpro inhibitors. Moreover, they suggest a possible molecular mechanism to explain the beneficial effect of arginine in COVIDpatients. Conclusions: The findings of the current study are important because they help to identify COVID-19 treatments that areefficient, inexpensive, and have a favorable safety profile. The results of this study also suggest a possible adjuvant nutritional strategyfor COVID-19 that could be used in conjunction with pharmacological agents.
T2  - Frontiers in Bioscience - Landmark
T1  - Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination
VL  - 28
IS  - 1
SP  - 8
DO  - 10.31083/j.fbl2801008
ER  - 

@article{
author = "Đukić, Ivana and Kaličanin, Nevena and Senćanski, Milan V. and Pajović, Snežana B. and Milićević, Jelena S. and Prljić, Jelena and Paessler, Slobodan and Prodanović, Radivoje and Glišić, Sanja",
year = "2023",
abstract = "Drug resistance is a critical problem in health care that affects therapy outcomes and requires new approaches to drugdesign. SARS-CoV-2 Mpro mutations are of concern as they can potentially reduce therapeutic efficacy. Viral infections are amongst themany disorders for which nutraceuticals have been employed as an adjunct therapy. The aim of this study was to examine the potentialin vitro activity of L-arginine and vitamin C against SARS-CoV-2 Mpro. Methods: The Mpro inhibition assay was developed by cloning,expression, purification, and characterization of Mpro. Selected compounds were then screened for protease inhibition. Results: Largininewas found to be active against SARS-CoV-2 Mpro, while a vitamin C/L-arginine combination had a synergistic antiviral actionagainst Mpro. These findings confirm the results of our previous in silico repurposing study that showed L-arginine and vitamin C werepotential Mpro inhibitors. Moreover, they suggest a possible molecular mechanism to explain the beneficial effect of arginine in COVIDpatients. Conclusions: The findings of the current study are important because they help to identify COVID-19 treatments that areefficient, inexpensive, and have a favorable safety profile. The results of this study also suggest a possible adjuvant nutritional strategyfor COVID-19 that could be used in conjunction with pharmacological agents.",
journal = "Frontiers in Bioscience - Landmark",
title = "Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination",
volume = "28",
number = "1",
pages = "8",
doi = "10.31083/j.fbl2801008"
}

Đukić, I., Kaličanin, N., Senćanski, M. V., Pajović, S. B., Milićević, J. S., Prljić, J., Paessler, S., Prodanović, R.,& Glišić, S.. (2023). Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination. in Frontiers in Bioscience - Landmark, 28(1), 8.
https://doi.org/10.31083/j.fbl2801008

Đukić I, Kaličanin N, Senćanski MV, Pajović SB, Milićević JS, Prljić J, Paessler S, Prodanović R, Glišić S. Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination. in Frontiers in Bioscience - Landmark. 2023;28(1):8.
doi:10.31083/j.fbl2801008 .

Đukić, Ivana, Kaličanin, Nevena, Senćanski, Milan V., Pajović, Snežana B., Milićević, Jelena S., Prljić, Jelena, Paessler, Slobodan, Prodanović, Radivoje, Glišić, Sanja, "Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination" in Frontiers in Bioscience - Landmark, 28, no. 1 (2023):8,
https://doi.org/10.31083/j.fbl2801008 . .

TY  - JOUR
AU  - Protić, Sara
AU  - Kaličanin, Nevena
AU  - Senćanski, Milan
AU  - Prodanović, Olivera
AU  - Milićević, Jelena S.
AU  - Perović, Vladimir
AU  - Paessler, Slobodan
AU  - Prodanović, Radivoje
AU  - Glišić, Sanja
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10644
AB  - Finding an effective drug to prevent or treat COVID-19 is of utmost importance in tcurrentpandemic. Since developing a new treatment takes a significant amount of time, drug repurposingcan be an effective option for achieving a rapid response. This study used a combined in silico virtualscreening protocol for candidate SARS-CoV-2 PLpro inhibitors. The Drugbank database was searchedfirst, using the Informational Spectrum Method for Small Molecules, followed by molecular docking.Gramicidin D was selected as a peptide drug, showing the best in silico interaction profile with PLpro.After the expression and purification of PLpro, gramicidin D was screened for protease inhibitionin vitro and was found to be active against PLpro. The current study’s findings are significantbecause it is critical to identify COVID-19 therapies that are efficient, affordable, and have a favorablesafety profile.
T2  - International Journal of Molecular Sciences
T1  - In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D
VL  - 24
IS  - 3
SP  - 1955
DO  - 10.3390/ijms24031955
ER  - 

@article{
author = "Protić, Sara and Kaličanin, Nevena and Senćanski, Milan and Prodanović, Olivera and Milićević, Jelena S. and Perović, Vladimir and Paessler, Slobodan and Prodanović, Radivoje and Glišić, Sanja",
year = "2023",
abstract = "Finding an effective drug to prevent or treat COVID-19 is of utmost importance in tcurrentpandemic. Since developing a new treatment takes a significant amount of time, drug repurposingcan be an effective option for achieving a rapid response. This study used a combined in silico virtualscreening protocol for candidate SARS-CoV-2 PLpro inhibitors. The Drugbank database was searchedfirst, using the Informational Spectrum Method for Small Molecules, followed by molecular docking.Gramicidin D was selected as a peptide drug, showing the best in silico interaction profile with PLpro.After the expression and purification of PLpro, gramicidin D was screened for protease inhibitionin vitro and was found to be active against PLpro. The current study’s findings are significantbecause it is critical to identify COVID-19 therapies that are efficient, affordable, and have a favorablesafety profile.",
journal = "International Journal of Molecular Sciences",
title = "In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D",
volume = "24",
number = "3",
pages = "1955",
doi = "10.3390/ijms24031955"
}

Protić, S., Kaličanin, N., Senćanski, M., Prodanović, O., Milićević, J. S., Perović, V., Paessler, S., Prodanović, R.,& Glišić, S.. (2023). In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D. in International Journal of Molecular Sciences, 24(3), 1955.
https://doi.org/10.3390/ijms24031955

Protić S, Kaličanin N, Senćanski M, Prodanović O, Milićević JS, Perović V, Paessler S, Prodanović R, Glišić S. In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D. in International Journal of Molecular Sciences. 2023;24(3):1955.
doi:10.3390/ijms24031955 .

Protić, Sara, Kaličanin, Nevena, Senćanski, Milan, Prodanović, Olivera, Milićević, Jelena S., Perović, Vladimir, Paessler, Slobodan, Prodanović, Radivoje, Glišić, Sanja, "In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D" in International Journal of Molecular Sciences, 24, no. 3 (2023):1955,
https://doi.org/10.3390/ijms24031955 . .

TY  - JOUR
AU  - Senćanski, Milan
AU  - Perović, Vladimir
AU  - Milićević, Jelena S.
AU  - Todorović, Tamara
AU  - Prodanović, Radivoje
AU  - Veljković, Veljko
AU  - Paessler, Slobodan
AU  - Glišić, Sanja
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10425
AB  - In the currentpandemic,findingan effectivedrugto preventortreatthe infectionis the highestpriority.A rapidand safeapproachto counteractCOVID-19is in silicodrugrepurposing.The SARS-CoV-2PLpropromotesviral replicationand modu-latesthe hostimmunesystem,resultingin inhibitionof thehostantiviralinnateimmuneresponse,and thereforeis anattractivedrugtarget.In this study,we useda combinedinsilicovirtualscreeningfor candidatesfor SARS-CoV-2PLproproteaseinhibitors.We usedthe Informationalspectrummethodappliedfor SmallMoleculesfor searchingthe Drugbankdatabasefollowedby moleculardocking.Afterin silicoscreen-ing of drugspace,we identified44 drugsas potentialSARS-CoV-2PLproinhibitorsthat we proposefor furtherexperimentaltesting.
T2  - ChemistryOpen
T1  - Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach
VL  - 11
IS  - 2
SP  - e202100248
DO  - 10.1002/open.202100248
ER  - 

@article{
author = "Senćanski, Milan and Perović, Vladimir and Milićević, Jelena S. and Todorović, Tamara and Prodanović, Radivoje and Veljković, Veljko and Paessler, Slobodan and Glišić, Sanja",
year = "2022",
abstract = "In the currentpandemic,findingan effectivedrugto preventortreatthe infectionis the highestpriority.A rapidand safeapproachto counteractCOVID-19is in silicodrugrepurposing.The SARS-CoV-2PLpropromotesviral replicationand modu-latesthe hostimmunesystem,resultingin inhibitionof thehostantiviralinnateimmuneresponse,and thereforeis anattractivedrugtarget.In this study,we useda combinedinsilicovirtualscreeningfor candidatesfor SARS-CoV-2PLproproteaseinhibitors.We usedthe Informationalspectrummethodappliedfor SmallMoleculesfor searchingthe Drugbankdatabasefollowedby moleculardocking.Afterin silicoscreen-ing of drugspace,we identified44 drugsas potentialSARS-CoV-2PLproinhibitorsthat we proposefor furtherexperimentaltesting.",
journal = "ChemistryOpen",
title = "Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach",
volume = "11",
number = "2",
pages = "e202100248",
doi = "10.1002/open.202100248"
}

Senćanski, M., Perović, V., Milićević, J. S., Todorović, T., Prodanović, R., Veljković, V., Paessler, S.,& Glišić, S.. (2022). Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach. in ChemistryOpen, 11(2), e202100248.
https://doi.org/10.1002/open.202100248

Senćanski M, Perović V, Milićević JS, Todorović T, Prodanović R, Veljković V, Paessler S, Glišić S. Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach. in ChemistryOpen. 2022;11(2):e202100248.
doi:10.1002/open.202100248 .

Senćanski, Milan, Perović, Vladimir, Milićević, Jelena S., Todorović, Tamara, Prodanović, Radivoje, Veljković, Veljko, Paessler, Slobodan, Glišić, Sanja, "Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach" in ChemistryOpen, 11, no. 2 (2022):e202100248,
https://doi.org/10.1002/open.202100248 . .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Glišić, Sanja
AU  - Perović, Vladimir R.
AU  - Veljković, Milena
AU  - Paessler, Slobodan
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10295
AB  - A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the leading threat to global health. An effective antiviral could not only help those still vulnerable to the virus but could be a critical treatment if a virus emerges toward evading coronavirus disease 2019 (COVID-19) vaccines. Despite the significant efforts to test already-approved drugs for their potential to kill the virus, researchers found very few actually worked. Methods: The present report uses the electronic molecular descriptors, the quasi-valence number (AQVN), and the electron-ion interaction potential (EIIP), for the analysis of natural compounds with proven therapeutic activity against the COVID-19. Results: Based on the analysis of the electronic properties of natural compounds which are effective against SARS-CoV-2 virus the simple theoretical criterion for the selection of candidate compounds for the treatment of COVID-19 is proposed. Conclusions: The proposed theoretical criterion can be used for the identification and optimization of new lead compounds for the treatment of the COVID-19 disease and for the selection of the food and food supplements which could have a beneficial effect on COVID-19 patients.
T2  - Frontiers in Bioscience - Landmark
T1  - Simple Theoretical Criterion for Selection of Natural Compounds with Anti-COVID-19 Activity
VL  - 27
IS  - 5
SP  - 152
DO  - 10.31083/j.fbl2705152
ER  - 

@article{
author = "Veljković, Veljko and Glišić, Sanja and Perović, Vladimir R. and Veljković, Milena and Paessler, Slobodan",
year = "2022",
abstract = "A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the leading threat to global health. An effective antiviral could not only help those still vulnerable to the virus but could be a critical treatment if a virus emerges toward evading coronavirus disease 2019 (COVID-19) vaccines. Despite the significant efforts to test already-approved drugs for their potential to kill the virus, researchers found very few actually worked. Methods: The present report uses the electronic molecular descriptors, the quasi-valence number (AQVN), and the electron-ion interaction potential (EIIP), for the analysis of natural compounds with proven therapeutic activity against the COVID-19. Results: Based on the analysis of the electronic properties of natural compounds which are effective against SARS-CoV-2 virus the simple theoretical criterion for the selection of candidate compounds for the treatment of COVID-19 is proposed. Conclusions: The proposed theoretical criterion can be used for the identification and optimization of new lead compounds for the treatment of the COVID-19 disease and for the selection of the food and food supplements which could have a beneficial effect on COVID-19 patients.",
journal = "Frontiers in Bioscience - Landmark",
title = "Simple Theoretical Criterion for Selection of Natural Compounds with Anti-COVID-19 Activity",
volume = "27",
number = "5",
pages = "152",
doi = "10.31083/j.fbl2705152"
}

Veljković, V., Glišić, S., Perović, V. R., Veljković, M.,& Paessler, S.. (2022). Simple Theoretical Criterion for Selection of Natural Compounds with Anti-COVID-19 Activity. in Frontiers in Bioscience - Landmark, 27(5), 152.
https://doi.org/10.31083/j.fbl2705152

Veljković V, Glišić S, Perović VR, Veljković M, Paessler S. Simple Theoretical Criterion for Selection of Natural Compounds with Anti-COVID-19 Activity. in Frontiers in Bioscience - Landmark. 2022;27(5):152.
doi:10.31083/j.fbl2705152 .

Veljković, Veljko, Glišić, Sanja, Perović, Vladimir R., Veljković, Milena, Paessler, Slobodan, "Simple Theoretical Criterion for Selection of Natural Compounds with Anti-COVID-19 Activity" in Frontiers in Bioscience - Landmark, 27, no. 5 (2022):152,
https://doi.org/10.31083/j.fbl2705152 . .

TY  - JOUR
AU  - Senćanski, Milan V.
AU  - Perović, Vladimir R.
AU  - Pajović, Snežana B.
AU  - Adžić, Miroslav
AU  - Paessler, Slobodan
AU  - Glišić, Sanja
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9611
AB  - The SARS-CoV-2 outbreak caused an unprecedented global public health threat, having a high transmission rate with currently no drugs or vaccines approved. An alternative powerful additional approach to counteract COVID-19 is in silico drug repurposing. The SARS-CoV-2 main protease is essential for viral replication and an attractive drug target. In this study, we used the virtual screening protocol with both long-range and short-range interactions to select candidate SARS-CoV-2 main protease inhibitors. First, the Informational spectrum method applied for small molecules was used for searching the Drugbank database and further followed by molecular docking. After in silico screening of drug space, we identified 57 drugs as potential SARS-CoV-2 main protease inhibitors that we propose for further experimental testing. © 2020 by the authors.
T2  - Molecules
T1  - Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel in Silico Method
VL  - 25
IS  - 17
DO  - 10.3390/molecules25173830
ER  - 

@article{
author = "Senćanski, Milan V. and Perović, Vladimir R. and Pajović, Snežana B. and Adžić, Miroslav and Paessler, Slobodan and Glišić, Sanja",
year = "2020",
abstract = "The SARS-CoV-2 outbreak caused an unprecedented global public health threat, having a high transmission rate with currently no drugs or vaccines approved. An alternative powerful additional approach to counteract COVID-19 is in silico drug repurposing. The SARS-CoV-2 main protease is essential for viral replication and an attractive drug target. In this study, we used the virtual screening protocol with both long-range and short-range interactions to select candidate SARS-CoV-2 main protease inhibitors. First, the Informational spectrum method applied for small molecules was used for searching the Drugbank database and further followed by molecular docking. After in silico screening of drug space, we identified 57 drugs as potential SARS-CoV-2 main protease inhibitors that we propose for further experimental testing. © 2020 by the authors.",
journal = "Molecules",
title = "Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel in Silico Method",
volume = "25",
number = "17",
doi = "10.3390/molecules25173830"
}

Senćanski, M. V., Perović, V. R., Pajović, S. B., Adžić, M., Paessler, S.,& Glišić, S.. (2020). Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel in Silico Method. in Molecules, 25(17).
https://doi.org/10.3390/molecules25173830

Senćanski MV, Perović VR, Pajović SB, Adžić M, Paessler S, Glišić S. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel in Silico Method. in Molecules. 2020;25(17).
doi:10.3390/molecules25173830 .

Senćanski, Milan V., Perović, Vladimir R., Pajović, Snežana B., Adžić, Miroslav, Paessler, Slobodan, Glišić, Sanja, "Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel in Silico Method" in Molecules, 25, no. 17 (2020),
https://doi.org/10.3390/molecules25173830 . .

TY  - JOUR
AU  - Matejin, Stanislava
AU  - Bukreyeva, Natalya
AU  - Radošević, Draginja
AU  - Senćanski, Milan V.
AU  - Mantlo, Emily
AU  - Veljković, Veljko
AU  - Glišić, Sanja
AU  - Paessler, Slobodan
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9036
AB  - Background: Due to the limitations of current antiviral therapies because of drug resistance and the emergence of new circulating viral strains, novel effective antivirals are urgently needed. Results of the previous drug repurposing by virtual screening of DrugBank revealed the anticholinergic drug cycrimine as a possible inhibitor of the influenza virus infection. Methods: In this study we examined the potential antiviral activity of cycrimine in vitro. Results: The experimental results showed the anti-influenza activity of cycrimine against two different influenza A subtypes in cell culture. Conclusions: The findings of this study suggest cycrimine as a potential therapeutic agent for influenza. ©2019 International Medical Press.
T2  - Antiviral Therapy
T1  - In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine
VL  - 24
IS  - 8
SP  - 589
EP  - 593
DO  - 10.3851/IMP3348
ER  - 

@article{
author = "Matejin, Stanislava and Bukreyeva, Natalya and Radošević, Draginja and Senćanski, Milan V. and Mantlo, Emily and Veljković, Veljko and Glišić, Sanja and Paessler, Slobodan",
year = "2020",
abstract = "Background: Due to the limitations of current antiviral therapies because of drug resistance and the emergence of new circulating viral strains, novel effective antivirals are urgently needed. Results of the previous drug repurposing by virtual screening of DrugBank revealed the anticholinergic drug cycrimine as a possible inhibitor of the influenza virus infection. Methods: In this study we examined the potential antiviral activity of cycrimine in vitro. Results: The experimental results showed the anti-influenza activity of cycrimine against two different influenza A subtypes in cell culture. Conclusions: The findings of this study suggest cycrimine as a potential therapeutic agent for influenza. ©2019 International Medical Press.",
journal = "Antiviral Therapy",
title = "In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine",
volume = "24",
number = "8",
pages = "589-593",
doi = "10.3851/IMP3348"
}

Matejin, S., Bukreyeva, N., Radošević, D., Senćanski, M. V., Mantlo, E., Veljković, V., Glišić, S.,& Paessler, S.. (2020). In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine. in Antiviral Therapy, 24(8), 589-593.
https://doi.org/10.3851/IMP3348

Matejin S, Bukreyeva N, Radošević D, Senćanski MV, Mantlo E, Veljković V, Glišić S, Paessler S. In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine. in Antiviral Therapy. 2020;24(8):589-593.
doi:10.3851/IMP3348 .

Matejin, Stanislava, Bukreyeva, Natalya, Radošević, Draginja, Senćanski, Milan V., Mantlo, Emily, Veljković, Veljko, Glišić, Sanja, Paessler, Slobodan, "In vitro anti-influenza activity of in silico repurposed candidate drug Cycrimine" in Antiviral Therapy, 24, no. 8 (2020):589-593,
https://doi.org/10.3851/IMP3348 . .

TY  - JOUR
AU  - Glišić, Sanja
AU  - Perović, Vladimir R.
AU  - Senćanski, Milan V.
AU  - Paessler, Slobodan
AU  - Veljković, Veljko
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9723
AB  - The Bacillus Calmette–Guerin vaccine is still widely used in the developing world. The vaccination prevents infant death not only from tuberculosis but also from unrelated infectious agents, especially respiratory tract infections and neonatal sepsis. It is proposed that these off-target protective effects of the BCG vaccine are mediated by the general long-term boosting of innate immune mechanisms, also termed “trained innate immunity”. Recent studies indicate that both COVID-19 incidence and total deaths are strongly associated with the presence or absence of national mandatory BCG vaccination programs and encourage the initiation of several clinical studies with the expectation that revaccination with BCG could reduce the incidence and severity of COVID-19. Here, presented results from the bioinformatics analysis of the Mycobacterium bovis (strain BCG/Pasteur 1173P2) proteome suggests four immunodominant antigens that could induce an immune response against SARS-CoV-2.
T2  - Journal of Proteome Research
T2  - Journal of Proteome ResearchJ. Proteome Res.
T1  - Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2
VL  - 19
IS  - 11
SP  - 4649
EP  - 4654
DO  - 10.1021/acs.jproteome.0c00410
ER  - 

@article{
author = "Glišić, Sanja and Perović, Vladimir R. and Senćanski, Milan V. and Paessler, Slobodan and Veljković, Veljko",
year = "2020",
abstract = "The Bacillus Calmette–Guerin vaccine is still widely used in the developing world. The vaccination prevents infant death not only from tuberculosis but also from unrelated infectious agents, especially respiratory tract infections and neonatal sepsis. It is proposed that these off-target protective effects of the BCG vaccine are mediated by the general long-term boosting of innate immune mechanisms, also termed “trained innate immunity”. Recent studies indicate that both COVID-19 incidence and total deaths are strongly associated with the presence or absence of national mandatory BCG vaccination programs and encourage the initiation of several clinical studies with the expectation that revaccination with BCG could reduce the incidence and severity of COVID-19. Here, presented results from the bioinformatics analysis of the Mycobacterium bovis (strain BCG/Pasteur 1173P2) proteome suggests four immunodominant antigens that could induce an immune response against SARS-CoV-2.",
journal = "Journal of Proteome Research, Journal of Proteome ResearchJ. Proteome Res.",
title = "Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2",
volume = "19",
number = "11",
pages = "4649-4654",
doi = "10.1021/acs.jproteome.0c00410"
}

Glišić, S., Perović, V. R., Senćanski, M. V., Paessler, S.,& Veljković, V.. (2020). Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2. in Journal of Proteome Research, 19(11), 4649-4654.
https://doi.org/10.1021/acs.jproteome.0c00410

Glišić S, Perović VR, Senćanski MV, Paessler S, Veljković V. Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2. in Journal of Proteome Research. 2020;19(11):4649-4654.
doi:10.1021/acs.jproteome.0c00410 .

Glišić, Sanja, Perović, Vladimir R., Senćanski, Milan V., Paessler, Slobodan, Veljković, Veljko, "Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2" in Journal of Proteome Research, 19, no. 11 (2020):4649-4654,
https://doi.org/10.1021/acs.jproteome.0c00410 . .

TY  - JOUR
AU  - Radošević, Draginja
AU  - Senćanski, Milan V.
AU  - Perović, Vladimir R.
AU  - Veljković, Nevena V.
AU  - Prljić, Jelena
AU  - Veljković, Veljko
AU  - Mantlo, Emily
AU  - Bukreyeva, Natalya
AU  - Paessler, Slobodan
AU  - Glišić, Sanja
PY  - 2019
UR  - https://www.frontiersin.org/article/10.3389/fcimb.2019.00067/full
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8163
AB  - Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture. © 2019 Radosevic, Sencanski, Perovic, Veljkovic, Prljic, Veljkovic, Mantlo, Bukreyeva, Paessler and Glisic.
T2  - Frontiers in Cellular and Infection Microbiology
T1  - Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors
VL  - 9
SP  - 67
DO  - 10.3389/fcimb.2019.00067
ER  - 

@article{
author = "Radošević, Draginja and Senćanski, Milan V. and Perović, Vladimir R. and Veljković, Nevena V. and Prljić, Jelena and Veljković, Veljko and Mantlo, Emily and Bukreyeva, Natalya and Paessler, Slobodan and Glišić, Sanja",
year = "2019",
abstract = "Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture. © 2019 Radosevic, Sencanski, Perovic, Veljkovic, Prljic, Veljkovic, Mantlo, Bukreyeva, Paessler and Glisic.",
journal = "Frontiers in Cellular and Infection Microbiology",
title = "Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors",
volume = "9",
pages = "67",
doi = "10.3389/fcimb.2019.00067"
}

Radošević, D., Senćanski, M. V., Perović, V. R., Veljković, N. V., Prljić, J., Veljković, V., Mantlo, E., Bukreyeva, N., Paessler, S.,& Glišić, S.. (2019). Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors. in Frontiers in Cellular and Infection Microbiology, 9, 67.
https://doi.org/10.3389/fcimb.2019.00067

Radošević D, Senćanski MV, Perović VR, Veljković NV, Prljić J, Veljković V, Mantlo E, Bukreyeva N, Paessler S, Glišić S. Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors. in Frontiers in Cellular and Infection Microbiology. 2019;9:67.
doi:10.3389/fcimb.2019.00067 .

Radošević, Draginja, Senćanski, Milan V., Perović, Vladimir R., Veljković, Nevena V., Prljić, Jelena, Veljković, Veljko, Mantlo, Emily, Bukreyeva, Natalya, Paessler, Slobodan, Glišić, Sanja, "Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors" in Frontiers in Cellular and Infection Microbiology, 9 (2019):67,
https://doi.org/10.3389/fcimb.2019.00067 . .

TY  - JOUR
AU  - Paessler, Slobodan
AU  - Huang, Cheng
AU  - Senćanski, Milan V.
AU  - Veljković, Nevena V.
AU  - Perović, Vladimir R.
AU  - Glišić, Sanja
AU  - Veljković, Veljko
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7695
AB  - The Ebola virus outbreak in West Africa 2015 and Congo 2017, point out an urgent need for development of drugs against this important pathogen. Previously, by repurposing virtual screening of 6438 drugs from DrugBank, ibuprofen was selected as a possible inhibitor of the Ebola virus infection. The results of an additional docking analysis as well as experimental results showing measurable anti-Ebola effect of ibuprofen in cell culture suggest ibuprofen as a promising molecular template for the development of drugs for treatment of the infection by Ebola virus.
T2  - Frontiers in Bioscience - Landmark
T1  - Ibuprofen as a template molecule for drug design against Ebola virus
VL  - 23
IS  - 5
SP  - 947
EP  - 953
UR  - https://hdl.handle.net/21.15107/rcub_vinar_7695
ER  - 

@article{
author = "Paessler, Slobodan and Huang, Cheng and Senćanski, Milan V. and Veljković, Nevena V. and Perović, Vladimir R. and Glišić, Sanja and Veljković, Veljko",
year = "2018",
abstract = "The Ebola virus outbreak in West Africa 2015 and Congo 2017, point out an urgent need for development of drugs against this important pathogen. Previously, by repurposing virtual screening of 6438 drugs from DrugBank, ibuprofen was selected as a possible inhibitor of the Ebola virus infection. The results of an additional docking analysis as well as experimental results showing measurable anti-Ebola effect of ibuprofen in cell culture suggest ibuprofen as a promising molecular template for the development of drugs for treatment of the infection by Ebola virus.",
journal = "Frontiers in Bioscience - Landmark",
title = "Ibuprofen as a template molecule for drug design against Ebola virus",
volume = "23",
number = "5",
pages = "947-953",
url = "https://hdl.handle.net/21.15107/rcub_vinar_7695"
}

Paessler, S., Huang, C., Senćanski, M. V., Veljković, N. V., Perović, V. R., Glišić, S.,& Veljković, V.. (2018). Ibuprofen as a template molecule for drug design against Ebola virus. in Frontiers in Bioscience - Landmark, 23(5), 947-953.
https://hdl.handle.net/21.15107/rcub_vinar_7695

Paessler S, Huang C, Senćanski MV, Veljković NV, Perović VR, Glišić S, Veljković V. Ibuprofen as a template molecule for drug design against Ebola virus. in Frontiers in Bioscience - Landmark. 2018;23(5):947-953.
https://hdl.handle.net/21.15107/rcub_vinar_7695 .

Paessler, Slobodan, Huang, Cheng, Senćanski, Milan V., Veljković, Nevena V., Perović, Vladimir R., Glišić, Sanja, Veljković, Veljko, "Ibuprofen as a template molecule for drug design against Ebola virus" in Frontiers in Bioscience - Landmark, 23, no. 5 (2018):947-953,
https://hdl.handle.net/21.15107/rcub_vinar_7695 .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Veljković, Nevena V.
AU  - Paessler, Slobodan
AU  - Goeijenbier, Marco
AU  - Perović, Vladimir R.
AU  - Glišić, Sanja
AU  - Muller, Claude P.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1300
AB  - Influenza A virus (IAV) subtypes against which little or no pre-existing immunity exists in humans represent a serious threat to global public health. Monitoring of IAV in animal hosts is essential for early and rapid detection of potential pandemic IAV strains to prevent their spread. Recently, the increased pandemic potential of the avian-like swine H1N1 IAV A/swine/Guangdong/104/2013 has been suggested. The virus is infectious in humans and the general population seems to lack neutralizing antibodies against this virus. Here we present an in silico analysis that shows a strong human propensity of this swine virus further confirming its pandemic potential. We suggest mutations which would further enhance its human propensity. We also propose conserved antigenic determinants which could serve as a component of a prepandemic vaccine. The bioinformatics tool, which can be used to further monitor the evolution of swine influenza viruses towards a pandemic virus, are described here and are made publically available (http://www.vin.bg.ac.rs/180/tools/iav_ mon.php;http://www.biomedprotection.com/iav_mon.php).
T2  - PLOS One
T1  - Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China
VL  - 11
IS  - 11
DO  - 10.1371/journal.pone.0165451
ER  - 

@article{
author = "Veljković, Veljko and Veljković, Nevena V. and Paessler, Slobodan and Goeijenbier, Marco and Perović, Vladimir R. and Glišić, Sanja and Muller, Claude P.",
year = "2016",
abstract = "Influenza A virus (IAV) subtypes against which little or no pre-existing immunity exists in humans represent a serious threat to global public health. Monitoring of IAV in animal hosts is essential for early and rapid detection of potential pandemic IAV strains to prevent their spread. Recently, the increased pandemic potential of the avian-like swine H1N1 IAV A/swine/Guangdong/104/2013 has been suggested. The virus is infectious in humans and the general population seems to lack neutralizing antibodies against this virus. Here we present an in silico analysis that shows a strong human propensity of this swine virus further confirming its pandemic potential. We suggest mutations which would further enhance its human propensity. We also propose conserved antigenic determinants which could serve as a component of a prepandemic vaccine. The bioinformatics tool, which can be used to further monitor the evolution of swine influenza viruses towards a pandemic virus, are described here and are made publically available (http://www.vin.bg.ac.rs/180/tools/iav_ mon.php;http://www.biomedprotection.com/iav_mon.php).",
journal = "PLOS One",
title = "Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China",
volume = "11",
number = "11",
doi = "10.1371/journal.pone.0165451"
}

Veljković, V., Veljković, N. V., Paessler, S., Goeijenbier, M., Perović, V. R., Glišić, S.,& Muller, C. P.. (2016). Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China. in PLOS One, 11(11).
https://doi.org/10.1371/journal.pone.0165451

Veljković V, Veljković NV, Paessler S, Goeijenbier M, Perović VR, Glišić S, Muller CP. Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China. in PLOS One. 2016;11(11).
doi:10.1371/journal.pone.0165451 .

Veljković, Veljko, Veljković, Nevena V., Paessler, Slobodan, Goeijenbier, Marco, Perović, Vladimir R., Glišić, Sanja, Muller, Claude P., "Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China" in PLOS One, 11, no. 11 (2016),
https://doi.org/10.1371/journal.pone.0165451 . .

TY  - JOUR
AU  - Glišić, Sanja
AU  - Paessler, Slobodan
AU  - Veljković, Nevena V.
AU  - Perović, Vladimir R.
AU  - Prljić, Jelena
AU  - Veljković, Veljko
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/709
AB  - Introduction: The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used. Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs. Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro- and in sllico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.
T2  - Expert Opinion on Drug Discovery
T1  - Improving attrition rates in Ebola virus drug discovery
VL  - 10
IS  - 9
SP  - 1025
EP  - 1032
DO  - 10.1517/17460441.2015.1062872
ER  - 

@article{
author = "Glišić, Sanja and Paessler, Slobodan and Veljković, Nevena V. and Perović, Vladimir R. and Prljić, Jelena and Veljković, Veljko",
year = "2015",
abstract = "Introduction: The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used. Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs. Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro- and in sllico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.",
journal = "Expert Opinion on Drug Discovery",
title = "Improving attrition rates in Ebola virus drug discovery",
volume = "10",
number = "9",
pages = "1025-1032",
doi = "10.1517/17460441.2015.1062872"
}

Glišić, S., Paessler, S., Veljković, N. V., Perović, V. R., Prljić, J.,& Veljković, V.. (2015). Improving attrition rates in Ebola virus drug discovery. in Expert Opinion on Drug Discovery, 10(9), 1025-1032.
https://doi.org/10.1517/17460441.2015.1062872

Glišić S, Paessler S, Veljković NV, Perović VR, Prljić J, Veljković V. Improving attrition rates in Ebola virus drug discovery. in Expert Opinion on Drug Discovery. 2015;10(9):1025-1032.
doi:10.1517/17460441.2015.1062872 .

Glišić, Sanja, Paessler, Slobodan, Veljković, Nevena V., Perović, Vladimir R., Prljić, Jelena, Veljković, Veljko, "Improving attrition rates in Ebola virus drug discovery" in Expert Opinion on Drug Discovery, 10, no. 9 (2015):1025-1032,
https://doi.org/10.1517/17460441.2015.1062872 . .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Paessler, Slobodan
AU  - Glišić, Sanja
AU  - Prljić, Jelena
AU  - Perović, Vladimir R.
AU  - Veljković, Nevena V.
AU  - Scotch, Matthew
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/863
AB  - A key factor in the effectiveness of the seasonal influenza vaccine is its immunological compatibility with the circulating viruses during the season. Here we propose a new bioinformatics approach for analysis of influenza viruses which could be used as an efficient tool for selection of vaccine viruses, assessment of the effectiveness of seasonal influenza vaccines, and prediction of the epidemic/pandemic potential of novel influenza viruses.
T2  - Frontiers in Microbiology
T1  - Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic
VL  - 6
DO  - 10.3389/fmicb.2015.01456
ER  - 

@article{
author = "Veljković, Veljko and Paessler, Slobodan and Glišić, Sanja and Prljić, Jelena and Perović, Vladimir R. and Veljković, Nevena V. and Scotch, Matthew",
year = "2015",
abstract = "A key factor in the effectiveness of the seasonal influenza vaccine is its immunological compatibility with the circulating viruses during the season. Here we propose a new bioinformatics approach for analysis of influenza viruses which could be used as an efficient tool for selection of vaccine viruses, assessment of the effectiveness of seasonal influenza vaccines, and prediction of the epidemic/pandemic potential of novel influenza viruses.",
journal = "Frontiers in Microbiology",
title = "Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic",
volume = "6",
doi = "10.3389/fmicb.2015.01456"
}

Veljković, V., Paessler, S., Glišić, S., Prljić, J., Perović, V. R., Veljković, N. V.,& Scotch, M.. (2015). Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic. in Frontiers in Microbiology, 6.
https://doi.org/10.3389/fmicb.2015.01456

Veljković V, Paessler S, Glišić S, Prljić J, Perović VR, Veljković NV, Scotch M. Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic. in Frontiers in Microbiology. 2015;6.
doi:10.3389/fmicb.2015.01456 .

Veljković, Veljko, Paessler, Slobodan, Glišić, Sanja, Prljić, Jelena, Perović, Vladimir R., Veljković, Nevena V., Scotch, Matthew, "Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic" in Frontiers in Microbiology, 6 (2015),
https://doi.org/10.3389/fmicb.2015.01456 . .